Is NCT02860650 results overdue?

Yes — results are overdue. Primary completion was 2017-05; the FDAAA-801 reporting deadline (2018-05-31) passed 2943 days ago and no results are posted on ClinicalTrials.gov.

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

NCT ID	NCT02860650 ↗
Sponsor	Janssen Vaccines & Prevention B.V. (INDUSTRY)
Phase	PHASE1
Status	COMPLETED
Primary completion	2017-05 (ACTUAL)
Reporting deadline	2018-05-31 (completion + 365d)
Days overdue	2943
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `23c3cbf75c3672c7…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02860650. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.